Stock IKNA IKENA ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Ikena Oncology, Inc.

Equities

IKNA

US45175G1085

Market Closed - Nasdaq
Other stock markets
 01:30:00 02/05/2024 am IST 		5-day change 1st Jan Change
1.3 USD -1.52% Intraday chart for Ikena Oncology, Inc. +0.78% -34.01%
12/03 Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
12/03 North American Morning Briefing : Inflation Data -2- DJ

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Ikena Oncology, Inc. Announces Executive Changes
Ikena Oncology, Inc. Provides Corporate Updates
Top Premarket Decliners
Ikena Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Ikena Oncology, Inc. Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial
Ikena Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Ikena Oncology Shares Fall After Pionyr Immunotherapeutics Acquisition Completed
Ikena Oncology Completes Acquisition of Pionyr Immunotherapeutics in All-Stock Deal
Ikena Oncology, Inc. acquired Pionyr Immunotherapeutics Inc..
Ikena Oncology Prices $40 Million Underwritten Offering
Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Ikena Oncology, Inc. Announces Preclinical Data in the Novel Investigational Hippo Pathway Inhibitor, Ik-930
Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Ikena Oncology Presents Preclinical Data on Ik-595, Best-In-Class Next-Generation Mek-Raf Complex Inhibitor, in Plenary Session At Aacr Special Conference on Ras Targeting
Ikena Oncology Gets FDA Fast Track Label for IK-175 Plus Nivolumab to Treat Urothelial Carcinoma
Ikena Oncology, Inc. Receives FDA Fast Track Designation for Novel Ahr Antagonist Ik-175 in Combination with Nivolumab to Treat Urothelial Carcinoma
Ikena Oncology, Inc. Announces Board Changes
Top Premarket Gainers
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IKNA Stock
  4. News Ikena Oncology, Inc.
  5. Other languages